Table 1.
Baseline Clinical and Pathologic Characteristics, According to ECOG PS
| Characteristics | ECOG PS |
p Value | |
|---|---|---|---|
| <2 (n = 559) | ≥2 (n = 231) | ||
| Age, median (range) | 68 (33–88) | 68 (32–86) | 0.626 |
| Sex, n (%) | 0.141 | ||
| Female | 293 (52.5) | 108 (46.8) | |
| Male | 265 (47.5) | 123 (53.2) | |
| Smoking status, n (%) | 0.639 | ||
| Never | 42 (7.5) | 22 (9.5) | |
| Ever | 499 (89.3) | 202 (87.4) | |
| Unknown | 18 (3.2) | 7 (3.0) | |
| Histology, n (%) | 0.145 | ||
| Adenocarcinoma | 416 (74.6) | 155 (67.1) | |
| Squamous | 105 (18.8) | 61 (26.4) | |
| Other | 37 (6.6) | 15 (6.5) | |
| Stage at diagnosis, n (%) | 0.168 | ||
| I/II | 72 (12.9) | 19 (8.2) | |
| III | 141 (25.2) | 59 (25.5) | |
| IV | 346 (61.9) | 153 (66.2) | |
| Site of metastases, n (%) | |||
| Brain | 0.715 | ||
| No | 474 (84.9) | 193 (83.9) | |
| Yes | 84 (15.1) | 37 (16.1) | |
| Liver | 0.003 | ||
| No | 467 (83.5) | 171 (74.3) | |
| Yes | 92 (16.5) | 59 (25.7) | |
| Bone | 0.040 | ||
| No | 392 (70.1) | 144 (62.6) | |
| Yes | 167 (29.9) | 86 (37.4) | |
| Line of therapy, n (%) | <0.001 | ||
| 1 | 325 (58.1) | 102 (44.2) | |
| 2+ | 234 (41.9) | 129 (55.8) | |
| Treatment agent, n (%) | 0.127 | ||
| Nivolumab | 186 (33.3) | 90 (39.0) | |
| Pembrolizumab | 373 (66.7) | 141 (61.0) | |
| PD-L1 expression, n (%) | 0.671 | ||
| <1% | 86 (15.4) | 30 (13.0) | |
| 1%–49% | 86 (15.4) | 42 (18.2) | |
| ≥50% | 277 (49.7) | 112 (48.5) | |
| Unknown | 108 (19.4) | 47 (20.3) | |
ECOG PS, Eastern Cooperative Group Performance Status; PD-L1, programmed death-ligand 1.